Efficacy and ADRs to first-line biologics prescribed for relapsing polychondritis in 41 patients
| Exposures to biologics | Response achieved during first 6 months, n (%) | CR achieved during first 6 months, n (%) | Decrease in CS dose at M6, mg PEQ, median (range)* | Follow-up, months, median (range) | Discontinuation of biologic | |||
| Overall n (%) | Insufficient efficacy n (%) | Loss of efficacy n (%) | ADR n (%) | |||||
| Overall (n=41) | 27 (65.8) | 12 (29.3) | −5.0 (–72.5;+10.0) | 6.0 (0.4–80.8) | 29 (70.7) | 14 (34.1) | 8 (27.6) | 9 (21.9) |
| TNF antagonists (n=30) | 19 (63.3) | 9 (30.0) | −5 (−53;+10) | 6.5 (0.4–80.8) | 25 (83.3) | 12 (40.0) | 8 (26.7) | 7 (23.3) |
| Infliximab (n=11) | 6 (54.5) | 5 (45.4) | −2.5 (–15;+0) | 7.0 (0.7–80.8) | 9 (81.8) | 5 (45.4) | 2 (18.2) | 1 (9.1) |
| Adalimumab (n=12) | 8 (66.7) | 4 (33.3) | −10 (−53;+10) | 13.6 (0.4–71.7) | 10 (83.3) | 3 (25.0) | 4 (33.3) | 3 (25.0) |
| Etanercept (n=7) | 5 (71.4) | 0 | −2.5 (–5;+0) | 5.5 (0.7–36.7) | 7 (100) | 4 (57.1) | 2 (85.7) | 3 (42.9) |
| Tocilizumab (n=5) | 4 (80.0) | 2 (40.0) | −37.2 (–72.5;+2) | 1.8 (0.4–11.5) | 3 (60.0) | 1 (20.0) | 0 | 1 (20.0) |
| Rituximab (n=4) | 3 (75.0) | 0 | −1 (−5;+5) | 6.0 | 2 (50.0) | 2 (50.0) | – | – |
| Anakinra (n=1) | 1 (100) | 1 (100) | −25 | 63.8 | 0 | 0 | 0 | 0 |
| Abatacept (n=1) | 0 | 0 | – | 1.8 | 1 (100) | 1 (100) | 0 | 0 |
*Data available for seven patients receiving infliximab, nine on adalimumab, four on etanercept, one on anakinra, four on rituximab, two on tocilizumab and none on abatacept.
ADR, adverse drug reaction; CR, complete response; CS, corticosteroids; PEQ, prednisone equivalent;TNF, tumour necrosis factor.